copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

What is the mechanism of action (MOA) for Otezla® (apremilast) in plaque psoriasis?

OTEZLA IS A NON-BIOLOGIC ORAL PDE4 INHIBITOR WITH A DISTINCT MOA FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.1

Otezla works by inhibiting phosphodiesterase 4 (PDE4) intracellularly and has anti-inflammatory properties.1-4 By elevating cyclic adenosine monophosphate (cAMP) levels, Otezla is thought to indirectly modulate production of pro-inflammatory and anti-inflammatory mediators.3

PDE4 and cAMP

Learn more about the role of phosphodiesterase 4 (PDE4) and cAMP in controlling inflammation.2-7

View the PDE4 MOA

Otezla MOA

Learn how Otezla’s inhibition of PDE4 within cells affects the production of inflammatory mediators.1,3,4

Review the Otezla MOA

The specific mechanism(s) by which Otezla exerts its therapeutic action in patients with psoriasis are not well defined.1

References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation. 2. Schafer PH, Parton A, Gandhi AK, et al. Br J Pharm. 2010;159(4):842-855. 3. Schafer PH, Parton A, Capone L, et al. Cell Signal. 2014;26(9):2016-2029. 4. Schafer P. Biochem Pharmacol. 2012;83(12):1583-1590. 5. Schett G, Sloan VS, Stevens RM, Schafer P. Ther Adv Musculoskelet Dis. 2010;2(5):271-278. 6. Gottlieb AB, Matheson RT, Menter A, et al. J Drugs Dermatol. 2013;12(8):888-897. 7. Moore AR, Willoughby DA. Clin Exp Immunol. 1995;101(3):387-389.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a
Healthcare Professional?

Getting Otezla Gets Even Easier

8 out of 10commercially insured lives in the US have preferred access with no biologic step required for Otezla® (apremilast)1

Click here for a complete list of plans
Reference: 1. Data on file, Celgene Corporation.
01/18 USII-APR180063